Minden Kirsten
Children's University Hospital Charité Berlin and Epidemiology Unit, German Rheumatism Research Centre, Berlin DE-13353, Germany.
Horm Res. 2009 Nov;72 Suppl 1:20-5. doi: 10.1159/000229759. Epub 2009 Nov 27.
Knowledge of the long-term outcomes of patients with juvenile idiopathic arthritis (JIA) has evolved during the past decade. Recent studies, using standardized classification criteria, new and reliable outcome measures and improved methods of statistical analyses, show that outcomes are still less than ideal. Approximately half of all young adults with JIA have ongoing active disease and over one third experience detectable degrees of disability and organ damage. These patients also show a distinctive pattern of growth disturbances. Most patients with general growth failure have systemic or polyarticular disease: significant short stature (final height standard deviation score <-2) has been noted in 41% of patients with systemic JIA and in 11% of patients with polyarticular JIA. In contrast, localized growth disturbances can be seen in patients with oligoarthritis.
Despite its name, JIA can be a lifelong disorder. With early and more widespread use of biological and other innovative therapies, however, outcomes for patients with JIA should improve further.
在过去十年中，青少年特发性关节炎（JIA）患者长期预后的相关知识不断发展。近期研究采用标准化分类标准、新的可靠结局指标及改进的统计分析方法，结果显示预后仍不尽人意。所有患有JIA的年轻成年人中，约一半存在持续性活动性疾病，超过三分之一有可检测到的残疾程度和器官损害。这些患者还呈现出独特的生长发育障碍模式。大多数生长发育迟缓的患者患有全身性或多关节疾病：41%的全身型JIA患者和11%的多关节型JIA患者出现显著身材矮小（最终身高标准差评分<-2）。相比之下，少关节型患者可出现局部生长发育障碍。
尽管名为青少年特发性关节炎，但它可能是一种终身性疾病。然而，随着生物制剂和其他创新疗法的早期更广泛应用，JIA患者的预后应会进一步改善。
